QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Positioned in Growing Markets with Novel Therapies and Groundbreaking Delivery Platform

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is positioned in rapidly-growing markets with innovative preventative therapies and a groundbreaking cannabidiol (“CBD”) drug delivery platform. An article discussing this reads, “Research has shown CBD to be non-psychoactive and to have anti-inflammatory, anti-anxiety and anti-emetic properties (http://ibn.fm/KnsIZ). Following nasal administration, the formulations gel rapidly with mucosal tissue to facilitate direct nose-to-brain delivery of cannabinoids. The gel substantially improves bioavailability and provides controlled cannabinoid release, staying in the nasal passages for up to seven days.”

To view the full article, visit http://ibn.fm/XczQC

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com